Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43927114" target="_blank" >RIV/00064173:_____/24:43927114 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/24:43927114

Výsledek na webu

<a href="https://doi.org/10.1111/ijd.17285" target="_blank" >https://doi.org/10.1111/ijd.17285</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ijd.17285" target="_blank" >10.1111/ijd.17285</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma

Popis výsledku v původním jazyce

Immunotherapy with checkpoint inhibitors is considered the golden standard not only for adjuvant setting of high-risk melanoma (stage III/IV) but also for palliative treatment of advanced melanoma. In spite of the high efficacy of this therapy, in at least 50% of patients with high-risk melanoma in stage III or with advanced melanoma in stage IV, a failure of therapy occurs. A single-center prospective observational study was conducted with 18 adults with advanced malignant melanoma after previous failure of anti-PD-1 +/- anti-CTLA-4 treatment in the adjuvant or palliative setting (Table 1). This study received the approval of the Ethics Committee, and all subjects provided written informed consent. Patients were enrolled between January 1, 2021, and December 31, 2023. Lenvatinib and pembrolizumab combination therapy was initiated, where lenvatinib was administered in a dose of 20 mg per day, and pembrolizumab was applied in a flat dose of 200 mg IV infusion every 3 weeks. The objective response rate (ORR-complete response/CR + partial response/PR) was the primary endpoint. The progression-free survival (PFS), the overall survival (OS), and the safety profiles were the secondary endpoints.

Název v anglickém jazyce

Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma

Popis výsledku anglicky

Immunotherapy with checkpoint inhibitors is considered the golden standard not only for adjuvant setting of high-risk melanoma (stage III/IV) but also for palliative treatment of advanced melanoma. In spite of the high efficacy of this therapy, in at least 50% of patients with high-risk melanoma in stage III or with advanced melanoma in stage IV, a failure of therapy occurs. A single-center prospective observational study was conducted with 18 adults with advanced malignant melanoma after previous failure of anti-PD-1 +/- anti-CTLA-4 treatment in the adjuvant or palliative setting (Table 1). This study received the approval of the Ethics Committee, and all subjects provided written informed consent. Patients were enrolled between January 1, 2021, and December 31, 2023. Lenvatinib and pembrolizumab combination therapy was initiated, where lenvatinib was administered in a dose of 20 mg per day, and pembrolizumab was applied in a flat dose of 200 mg IV infusion every 3 weeks. The objective response rate (ORR-complete response/CR + partial response/PR) was the primary endpoint. The progression-free survival (PFS), the overall survival (OS), and the safety profiles were the secondary endpoints.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Dermatology

ISSN

0011-9059

e-ISSN

1365-4632

Svazek periodika

63

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

2

Strana od-do

"e219"-"e220"

Kód UT WoS článku

001242596900001

EID výsledku v databázi Scopus

2-s2.0-85195565746